Raymond James raised the firm's price target on AxoGen to $48 from $41 and keeps an Outperform rating on the shares. Axogen is delivering its strongest growth in five years, supported by strong commercial execution, accelerated hiring, and rising physician engagement following its BLA approval, the analyst tells investors in a research note. The company remains early in realizing the full benefit of the BLA, with expectations for continued momentum and potential upside to guidance as the year progresses, the firm says.
